

# 1 **Transmission of Acute Respiratory Infections during Aerosol Generating Medical**

## 2 **Procedures (AGMPs): An updated review**

3 Jenine Leal<sup>1,2,3,4</sup>, Mark Hofmeister<sup>1,3</sup>, Liza Mastikhina<sup>1,3</sup>, John Taplin<sup>1,3</sup>, Joyce Li<sup>1,3</sup>, Brenlea  
4 Farkas<sup>1,3</sup>, Laura Dowsett<sup>1,3</sup>, Tom Noseworthy<sup>1,3</sup> and Fiona Clement<sup>1,3</sup>.

- 5 1. Department of Community Health Sciences, University of Calgary, Calgary, Alberta
- 6 Canada
- 7 2. Department of Microbiology, Immunology and Infectious Diseases, University of
- 8 Calgary, Calgary, Alberta Canada
- 9 3. O'Brien Institute for Public Health, University of Calgary, Calgary, Alberta Canada
- 10 4. Infection Prevention and Control, Alberta Health Services, Alberta Canada

12 Mark Hofmeister  
13 3D10, 3280 Hospital Drive NW  
14 Calgary, AB T2N 4Z6  
15 [mrhofmei@ucalgary.ca](mailto:mrhofmei@ucalgary.ca)

Joyce Li  
3D10, 3280 Hospital Drive NW  
Calgary, AB T2N 4Z6  
[joycli@ucalgary.ca](mailto:joycli@ucalgary.ca)

17 Liza Mastikhina  
18 3D10, 3280 Hospital Drive NW  
19 Calgary, AB T2N 4Z6  
20 [lmastikh@ucalgary.ca](mailto:lmastikh@ucalgary.ca)

Brenlea Farkas  
3D10, 3280 Hospital Drive NW  
Calgary, AB T2N 4Z6  
[brenlea.farkas@ucalgary.ca](mailto:brenlea.farkas@ucalgary.ca)

22 John Taplin  
23 3D10, 3280 Hospital Drive NW  
24 Calgary, AB T2N 4Z6  
25 [jgtaplin@ucalgary.ca](mailto:jgtaplin@ucalgary.ca)

Laura Dowsett  
3D10, 3280 Hospital Drive NW  
Calgary, AB T2N 4Z6  
[lelegget@ucalgary.ca](mailto:lelegget@ucalgary.ca)

26 Tom Noseworthy  
27 3D10, 3280 Hospital Drive NW  
28 Calgary, AB T2N 4Z6  
29 [tnosewor@ucalgary.ca](mailto:tnosewor@ucalgary.ca)

Fiona Clement  
3D10, 3280 Hospital Drive NW  
Calgary, AB T2N 4Z6  
[fclement@ucalgary.ca](mailto:fclement@ucalgary.ca)

31 **Author Contributions Statement:** *Conceptualization of study:* JLeal. *Methodology:* JLeal,  
32 FClement, LDowsett, MHofmeister, LMastikhina, JTaplin, JLi, BFarkas. *Supervision:* FClement,  
33 TNoseworthy, JLeal. *Analysis:* LDowsett, MHofmeister, LMastikhina, JTaplin, JLi, BFarkas.  
34 *Writing of original draft:* JLeal, LDowsett, MHofmeister, LMastikhina, JTaplin, JLi, BFarkas.  
35 *Reviewing and editing draft:* FClement, TNoseworthy, MHofmeister, LDowsett, LMastikhina,  
36 JTaplin, JLi, BFarkas

37  
38 **Acknowledgment:** We would like to Dr. John Conly, the senior author of the original systematic  
39 review for reviewing and commenting on this update.

40 **Funding Statement:** The SPOR Evidence Alliance (SPOR EA) is supported by the Canadian  
41 Institutes of Health Research (CIHR) under the Strategy for Patient-Oriented Research (SPOR)  
42 initiative.

43  
44 COVID-19 Evidence Network to support Decision-making (COVID-END) is supported by the  
45 Canadian Institutes of Health Research (CIHR) through the Canadian 2019 Novel Coronavirus  
46 (COVID-19) Rapid Research Funding opportunity.

47  
48  
49 **Corresponding Author:**

50 Jenine Leal, PhD  
51 Foothills Medical Centre  
52 801 - South Tower  
53 3031 Hospital Drive NW  
54 Calgary, AB T2N 2T8  
55 Cell: (403) 973-6918  
56 Fax: (403) 944-3886  
57 Email: [jenine.leal@albertahealthservices.ca](mailto:jenine.leal@albertahealthservices.ca)

58  
59 Keywords: aerosol-generating procedures, acute respiratory infection, healthcare worker

60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81

82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106

## 1 ABSTRACT

**Objectives:** To review the literature from 2011 until March 31<sup>st</sup>, 2020 to identify the risk of transmission of ARIs to healthcare workers caring for patients undergoing AGMPs compared with the risk of transmission when caring for patients not undergoing AGMPs.

**Results:** Only two prospective cohort studies were identified meeting inclusion criteria. One found that performance or assistance with AGMP during the previous week was significantly associated with symptomatic influenza (adjusted OR: 2.29, 95% CI: 1.3 to 4.2). The second study found that performance of AGMP was significantly associated with clinical respiratory infections (RR 2.9, 95% CI 1.42-5.87, p<0.01), laboratory-confirmed virus or bacteria (RR 2.9, 95% CI 1.37-6.22, p=0.01), and laboratory-confirmed virus (RR 3.3, 95% CI 1.01-11.02, p=0.05). Further evidence is needed regarding what constitutes an AGMP and the risk of ARI transmission during presumed AGMPs. Organizations need to interpret these findings with caution when establishing AGMP lists requiring airborne precautions.

## 107 **2 INTRODUCTION**

108

109 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia (COVID-19) was  
110 first identified in December 2019 in Wuhan, China and has since spread globally. Available  
111 evidence suggests the primary route of human-to-human transmission of the SARS-CoV-2 virus  
112 is through large respiratory droplets and contact routes.[1, 2] This is supported by studies  
113 demonstrating transmission being highest within households,[2, 3] the absence of identified  
114 transmission on aircraft,[4] limited reports of significant outbreaks in staff of COVID-19  
115 treatment centres not using airborne precautions and N95 respirators.[5-7] Some studies have  
116 measured viral RNA in the air and air vents at enough distance from patients suggesting that  
117 aerosol transmission may be possible; however, whether the viral RNA in air represents living  
118 virus remains unknown.[8-13]

119

120 Certain medical procedures used in the treatment of acute respiratory infection (ARI) may  
121 increase the risk of aerosol generation from a patient above that of natural processes (coughing  
122 etc.).[14] The World Health Organization (WHO) and the Centers for Disease Control and  
123 Prevention (CDC) have identified several potentially aerosol generating procedures, which  
124 necessitate the use of airborne precautions such as N95 or higher respirators, in addition to  
125 gowns, gloves and eye protection along with airborne infection isolation room.[15, 16] However,  
126 there has been very limited research on which medical procedures should be considered aerosol-  
127 generating and the evidence defining relative risk of presumed AGMPs is insubstantial.[14, 17]

128

129 A systematic review on AGMPs and the associated risk of transmission of ARIs by Tran et al.  
130 (2012) identified that some procedures potentially capable of generating aerosols were associated

131 with increased risk of SARS transmission or were a risk factor for transmission.[18] Considering  
132 the COVID-19 pandemic, updated evidence is required on transmission of ARIs to HCWs due to  
133 aerosolized particles.

### 134 **3 MAIN TEXT**

135

#### 136 **3.1 Literature Search**

137 The search strategy by Tran et al. was updated by a research librarian to capture studies in  
138 MEDLINE, Embase, Cochrane Database of Systematic Reviews, Cochrane Central Register of  
139 Controlled Trials, and CINAHL published from 2011 to March 31<sup>st</sup>, 2020.[18] Terms related to  
140 AGMPs were combined with relevant disease terms and searched as text words in titles and  
141 abstracts and as MeSH subject headings, when applicable. The search excluded case reports,  
142 animal studies, conference abstracts, editorials, and letters. The full search strategy is reported in  
143 Additional File 1.

144

#### 145 **3.2 Literature Selection**

146

147 PRIMSA guidelines were followed (Additional File 2).[19] Abstracts identified were screened  
148 in duplicate and all included abstracts proceeded to full-text review. Full-text publications were  
149 screened in duplicate with discrepancies between reviewers resolved through consensus.  
150 Eligibility criteria included: 1) study population of HCWs caring for patients with ARIs,  
151 including but not limited to COVID-19, SARS, MERS, influenza, 2) the intervention was the  
152 provision of care to patients undergoing AGMPs, 3) comparator was the provision of care to  
153 patients not undergoing AGMPs, 4) the outcome was the risk of transmission of ARIs from

154 patients to HCWs and 5) the study design was a randomized controlled trial or non-randomized  
155 comparative study. Publications were excluded if they were not published in English or French.

156

### 157 **3.3 Data Extraction & Analysis**

158

159 For all included studies, year of publication, country, study design, population, aerosolizing  
160 procedure, period of evaluation, assessment of training and protective equipment, and number of  
161 exposed and non-exposed cases were extracted in duplicate using standardized data extraction  
162 forms. Discrepancies between reviewers during data extraction were resolved through consensus.  
163 Results of these studies were narratively synthesized.

164

### 165 **3.4 Results**

166

167 Searches of electronic databases yielded 7,299 records. The full texts of 59 records were  
168 screened, of which two records met inclusion/exclusion criteria (**Error! Reference source not  
169 found.**) (Table of excluded studies, in Additional File 3).

### 170 **Fig 1. Flow Chart of Included Studies**

171

172 Two prospective cohort studies were identified meeting inclusion criteria (Table 1).

173

174

175

176

177

178

179 Table 1. Characteristics of studies included

Study; Country	Design and Setting	Period of Evaluation	Population	Assessment of Training and Protection Equipment?	Laboratory Tests
Kuster et al.[20] 2013	Prospective Cohort  Acute Care Hospitals	2009 H1N1 pandemic in Toronto, Canada	563 HCW 169 non-HCW	Adherence to hand hygiene and facial protection based on recommendations	Hemagglutination-inhibition assay to determine antibody titers against the influenza virus A(H1N1)pdm09 strain (A/California/07/2009-like) and the 2008-09 seasonal influenza virus A(H1N1) strain (A/Brisbane/59/07)
MacIntyre et al.,[21] 2014	Prospective Cohort  Emergency and respiratory wards from nine hospitals	1 December 2008 to 15 January 2009 in Beijing, China	481 HCW	Hand washing, use of surgical masks or cloth masks (RR not reported), influenza vaccination	Viruses: <i>adenoviruses</i> , <i>human metapneumovirus</i> , <i>coronavirus 229E/NL63</i> and <i>OC43/HKU1</i> , <i>parainfluenza virus 1,2</i> , and <i>3</i> , <i>influenza virus A</i> and <i>B</i> , <i>respiratory syncytial virus A</i> and <i>B</i> , and <i>rhinovirus A/B</i> Bacteria: <i>Streptococcus pneumoniae</i> , <i>Mycoplasma pneumoniae</i> , <i>B. pertussis</i> , <i>Legionella</i> spp, <i>Chlamydia</i> and <i>Haemophilus influenzae</i> type B

180  
 181 The primary purpose of the study conducted in Toronto was to examine the epidemiology of  
 182 infection caused by influenza virus A(H1N1)pdm 09 among HCWs and other working adults in  
 183 Canada.[20] The authors secondarily determined risk factors for laboratory-confirmed  
 184 symptomatic influenza among HCWs. An AGMP was defined as any one of the following:  
 185 administration of nebulized therapy or humidified oxygen at >40%, use of bag-valve mask,  
 186 manual ventilation, non-invasive ventilation, open airway suctioning, bronchoscopy or other  
 187 upper airway endoscopy, tracheostomy, endotracheal intubation, cardiopulmonary resuscitation,  
 188 oscillatory ventilation, or any procedure that involved manipulation of open ventilatory tubing in  
 189 a mechanically ventilated patient, or sputum induction or other deliberate induction of  
 190 coughing.[20] In multivariate analysis adjusted for receipt of vaccine and dynamics of pandemic

191 waves, Kuster et al. (2013)[20] found that performance or assistance with AGMP during the  
192 previous week was significantly associated with symptomatic influenza (adjusted OR: 2.29, 95%  
193 CI: 1.3 to 4.2).[20]

194

195 In the second study, MacIntyre et al. (2014) prospectively studied 481 HCWs from emergency  
196 and respiratory wards from nine hospitals in Beijing China. Healthcare workers were subjects of  
197 a control group in a larger cluster randomized control trial (RCT) comparing fit-tested and non-  
198 fit tested N95 respirators to medical masks to prevent respiratory viral infection in HCWs. High  
199 risk procedures were defined as: provision of nebulizer medications, suctioning, intubation,  
200 AGMPs, and chest physiotherapy.[21] MacIntyre et al. (2014)[21] measured transmission of  
201 clinical respiratory infections defined as: presence of two or more respiratory symptoms; or, one  
202 respiratory symptom and one or more systemic symptoms. Laboratory-confirmation of viruses  
203 and bacteria included are listed in Table 1. Fifty-six (11.6%) HCWs performed at least one high  
204 risk procedure during the study, with the most common activity being airway suctioning (66%,  
205 37/56). Using Poisson regression, MacIntyre et al. (2014)[21] found that performance of AGMP  
206 was significantly associated with clinical respiratory infections (RR 2.9, 95% CI 1.42-5.87,  
207  $p < 0.01$ ), laboratory-confirmed virus or bacteria (RR 2.9, 95% CI 1.37-6.22,  $p = 0.01$ ), and  
208 laboratory-confirmed virus (RR 3.3, 95% CI 1.01-11.02,  $p = 0.05$ ).

209

### 210 **3.5 Discussion**

211

212 Two studies were identified in this update of the systematic review conducted by Tran et al.[18]  
213 Both additional studies concluded that the performance of AGMPs significantly increased risk of  
214 ARI transmission to HCWs.



215  
216 In both studies, there was a lack of power related to small number of cases of ARIs in the HCW  
217 groups and AGMPs were combined. Hence, risk could not be attributed to individual procedures  
218 as it was in the study by Tran et al. The study by Kuster et al (2013) was further limited by the  
219 potential of: enrollment bias with increased participation by individuals who perceive having a  
220 higher risk for influenza infection; recall bias with ill participants potentially reporting risk  
221 factors more accurately than people who did not develop the illness; and a Hawthorne effect  
222 whereby participants may have altered their behaviour (e.g. increased adherence to protective  
223 measures) as a result of participating in the study.[20] Although the participants in the MacIntyre  
224 et al. study were part of a control group of a cluster RCT, similar limitations such as recall bias  
225 may persist.[21]

226  
227 Interpretation of these findings is complicated by variation across jurisdictions in clinical care;  
228 quantity and type of AGMPs performed, infection prevention and control (IPC) practices,  
229 availability of personal protective equipment (PPE); type of PPE; and individual use and fit of  
230 PPE for each procedure. In addition to these sources of variation, validity of estimates from  
231 meta-analysis in the Tran et al. study was threatened by the very low quality of evidence  
232 available. Given this, the interpretation and practical application of the study findings is difficult.

233  
234 Despite the limited and insubstantial evidence on the types of procedures that constitute an  
235 AGMP and the risk associated with presumed AGMPs, many organizations and medical  
236 societies have taken a precautionary approach and adopted the full or partial list of procedures  
237 identified by Tran et al. (2012).[1, 16, 22, 23] The Infectious Disease Society of America

238 identified that there was no direct evidence of AGMPs and rates of COVID-19 infection among  
239 healthcare workers and that despite the very low quality and indirect evidence, they placed a high  
240 value on avoiding serious harms to exposed health care personnel.[23] They present the CDC  
241 and WHO's variable lists and rank the procedures from Tran et al. from highest odds ratio to  
242 lowest, despite many of the 95% confidence intervals crossing one and not being statistically  
243 significant.[23] A more transparent approach would be to present the results highlighting the  
244 procedures that have consistently demonstrated higher risk (e.g. Tracheal intubation). With the  
245 uncertainty and caution surrounding risk of transmission of SARS-CoV-2 among HCWs, other  
246 procedures have been proposed as potential AGMPs despite limited to no studies pertaining to  
247 their risk.[24-26] In our jurisdiction, a similar list of procedures was proposed by various clinical  
248 groups and societies. This list was reviewed by an expert working group made up of IPC  
249 physicians and professionals, workplace health and safety physicians, epidemiologists and  
250 respiratory therapists. Where decisions to exclude procedures as AGMPs differed from  
251 national/international clinical societies, engagement with these local groups occurred to establish  
252 consensus.[27] Other jurisdictions have employed similar processes to develop lists of  
253 AGMPs.[28] The result of including or excluding procedures as AGMPs using this approach will  
254 differ across jurisdictions depending on IPC guidelines and procedures, perceived risk of  
255 transmission and infection, and availability of PPE.

256

257 In the context of COVID-19, the evidence for HCW exposure through AGMPs is also limited  
258 and the generalizability of these findings to the current COVID-19 outbreak is unclear.[29] In a  
259 case control study among HCWs with acute respiratory symptoms working in the designated  
260 hospital of Wuhan University, HCW risk of developing COVID-19 was higher in areas where

261 AGMPs were performed (ICUs, respiratory wards, infection department and surgical  
262 department).[30] However, this risk was nullified when exposure was stratified by specific  
263 AGMPs (e.g. tracheal tube removal, sputum suction, fiber bronchoscopy). Additionally, HCW  
264 risk increased substantially on these units by self reported inadequate hand hygiene  
265 practices.[30] An epidemiological investigation was conducted of a patient diagnosed with  
266 COVID-19 after being nursed in an open ward with 10 other patients for 35 hours and being on  
267 high flow oxygen for 18.5 hours before being transferred to an airborne isolation room. Thirty-  
268 two of 71 staff developed respiratory symptoms but were all negative for SARS-CoV-2.[6] In  
269 another study, 41 HCWs were exposed to AGMPs for at least 10 minutes at a distance less than 2  
270 metres during the care of a retrospectively diagnosed COVID-19 patient in an ICU setting.[7]  
271 The AGMPs included endotracheal intubation, extubation, noninvasive ventilation and exposure  
272 to aerosols in an open circuit. A majority (85%) of exposed HCWs wore surgical masks, rather  
273 than N95 respirators, and followed standard contact and droplet precautions. None of the  
274 exposed HCWs developed symptoms and all tests for SARS-CoV-2 were negative. [7]

275

### 276 **3.6 Conclusion**

277

278 Like the Tran et al. review, this update finds the presence of a significant research gap which is  
279 further compounded by the lack of precision in the literature regarding the definition for  
280 AGMPs.[22] Further evidence is needed regarding the probability and types of infections  
281 following exposure, by type of procedure and PPE. Multidisciplinary teams should strive to use  
282 robust epidemiologic, engineering and aerodynamics or aerobiology study designs to identify  
283 associations between viral particles expelled and collected from aerosols generated by these  
284 procedures with viable virus capable of infecting susceptible hosts. This would enhance the

285 transferability of lessons learnt from AGMPs, whether from SARS, H1N1 or COVID-19 and  
286 prepare us for the next wave of COVID-19 or future pandemics of a respiratory nature.

287

#### 288 **4 LIMITATIONS**

289

290 This review has limitations given the expected rapid turnaround for completion. We were not  
291 able to search the grey literature for additional publications and we did not apply the GRADE  
292 assessment to the two studies. Individual AGMPs could not be delineated from the grouped  
293 analysis in the studies and therefore risk could not be assigned to individual procedures. The  
294 search strategy included terms and key words originally identified in the Tran et al. study;  
295 however, since the search, clinical societies have proposed the inclusion of other procedures,  
296 which were not included in the original search. However, many of these recommendations have  
297 not been substantiated by existing evidence so we do not think we have missed a significant  
298 portion of the literature.

299

300

301

302

303

304

305

306

307

308

## 309 LIST OF ABBREVIATIONS

310	AGMPs	aerosol-generating medical procedures
311	ARIs	acute respiratory infections
312	CDC	Center for Disease Control and Prevention
313	HCWs	healthcare workers
314	ICUs	intensive care units
315	IPC	infection prevention and control
316	OR	odds ratio
317	PPE	personal protective equipment
318	RCT	randomized control trial
319	RR	relative risk
320	SARS	severe acute respiratory syndrome
321	WHO	World Health Organization

322  
323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339 **5 DECLARATIONS**

340 **Ethics approval and consent to participate:** Not applicable

341 **Availability of data and material:** Not applicable. All data and material available in the  
342 manuscript.

343 **Funding:** Not applicable

344 **Acknowledgements:** We would like to Dr. John Conly, the senior author of the original  
345 systematic review for reviewing and commenting on this update.

346 **Consent for publication:** Not applicable

347 **Competing Interests:** The Authors declare that they have no competing interests.

348 **Authors' Contributions:** *Conceptualization of study:* JLeal. *Methodology:* JLeal, FClement,

349 LDowsett, MHofmeister, LMastikhina, JTaplin, JLi, BFarkas. *Supervision:* FClement,

350 TNoseworthy, JLeal. *Analysis:* LDowsett, MHofmeister, LMastikhina, JTaplin, JLi, BFarkas.

351 *Writing of original draft:* JLeal, LDowsett, MHofmeister, LMastikhina, JTaplin, JLi, BFarkas.

352 *Reviewing and editing draft:* FClement, TNoseworthy, MHofmeister, LDowsett, LMastikhina,

353 JTaplin, JLi, BFarkas

354

355

356

357

358

359

360

361

362

363

## 364 6 REFERENCES

365

- 366 1. World Health Organization. Coronavirus disease (COVID-19) technical guidance:  
367 Infection prevention and control. [Internet]. Geneva, Switzerland: World Health Organization;  
368 2020 [Available from: [https://www.who.int/emergencies/diseases/novel-coronavirus-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/infection-prevention-and-control)  
369 [2019/technical-guidance/infection-prevention-and-control](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/infection-prevention-and-control).  
370 2. World Health Organization. Report of the WHO-China Joint Mission on Coronavirus  
371 Disease 2019 (COVID-19). Geneva, Switzerland: World Health Organization; 2020 16-24  
372 February 2020.
- 373 3. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia  
374 associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of  
375 a family cluster. *Lancet*. 2020;395(10223):514-23.
- 376 4. Schwartz KL, Murti M, Finkelstein M, Leis J, Fitzgerald-Husek A, Bourns L, et al. Lack  
377 of COVID-19 transmission on an international flight 2020 24 March 2020. Available from:  
378 [https://www.cmaj.ca/content/192/7/E171/tab-e-letters#lack-of-covid-19-transmission-on-an-](https://www.cmaj.ca/content/192/7/E171/tab-e-letters#lack-of-covid-19-transmission-on-an-international-flight)  
379 [international-flight](https://www.cmaj.ca/content/192/7/E171/tab-e-letters#lack-of-covid-19-transmission-on-an-international-flight).
- 380 5. Canova V, Lederer Schlapfer H, Piso RJ, Droll A, Fenner L, Hoffmann T, et al.  
381 Transmission risk of SARS-CoV-2 to healthcare workers -observational results of a primary care  
382 hospital contact tracing. *Swiss Med Wkly*. 2020;150:w20257.
- 383 6. Wong SC, Kwong RT, Wu TC, Chan JWM, Chu MY, Lee SY, et al. Risk of nosocomial  
384 transmission of coronavirus disease 2019: an experience in a general ward setting in Hong Kong.  
385 *J Hosp Infect*. 2020.
- 386 7. Ng K, Poon BH, Kiat Puar TH, Shan Quah JL, Loh WJ, Wong YJ, et al. COVID-19 and  
387 the Risk to Health Care Workers: A Case Report. *Ann Intern Med*. 2020.
- 388 8. Santarpia JL, Rivera DN, Herrera V, Morwitzer MJ, Creager H, Santarpia GW, et al.  
389 Transmission Potential of SARS-CoV-2 in Viral Shedding Observed at the University of  
390 Nebraska Medical Center. *medRxiv*. [preprint]. In press 2020.
- 391 9. Liu Y, Ning Z, Chen Y, Guo M, Liu Y, Gali NK, et al. Aerodynamic analysis of SARS-  
392 CoV-2 in two Wuhan hospitals. *Nature*. 2020.
- 393 10. Guo ZD, Wang ZY, Zhang SF, Li X, Li L, Li C, et al. Aerosol and Surface Distribution  
394 of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospital Wards, Wuhan, China, 2020.  
395 *Emerg Infect Dis*. 2020;26(7).
- 396 11. Ong SWX, Tan YK, Chia PY, Lee TH, Ng OT, Wong MSY, et al. Air, Surface  
397 Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory  
398 Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient. *Jama*. 2020.
- 399 12. Faridi S, Niazi S, Sadeghi K, Naddafi K, Yavarian J, Shamsipour M, et al. A field indoor  
400 air measurement of SARS-CoV-2 in the patient rooms of the largest hospital in Iran. *Sci Total*  
401 *Environ*. 2020;725:138401.
- 402 13. Chia PY, Coleman KK, Tan YK, Ong SWX, Gum M, Lau SK, et al. Detection of Air and  
403 Surface Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in  
404 Hospital Rooms of Infected Patients. *medRxiv*. [preprint]. In press 2020.
- 405 14. Davies A, Thomson G, Walker J, Bennett A. A review of the risks and disease  
406 transmission associated with aerosol generating medical procedures. *J Infect Prev*.  
407 2009;10(4):122-6.

- 408 15. World Health Organization. Infection prevention and control during health care when  
409 novel coronavirus (nCoV) infection is suspected Geneva, Switzerland: World Health  
410 Organization; 2020 [Available from: [https://www.who.int/publications-detail/infection-](https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-(ncov)-infection-is-suspected-20200125)  
411 [prevention-and-control-during-health-care-when-novel-coronavirus-\(ncov\)-infection-is-](https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-(ncov)-infection-is-suspected-20200125)  
412 [suspected-20200125](https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-(ncov)-infection-is-suspected-20200125)].
- 413 16. Center for Disease Control and Prevention. Healthcare Infection Prevention and Control  
414 FAQs for COVID-19 Atlanta, United States 2020 [updated 20 May 2020. Available from:  
415 <https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-faq.html>].
- 416 17. Shiu EYC, Leung NHL, Cowling BJ. Controversy around airborne versus droplet  
417 transmission of respiratory viruses: implication for infection prevention. *Curr Opin Infect Dis*.  
418 2019;32(4):372-9.
- 419 18. Tran K, Cimon K, Severn M, Pessoa-Silva CL, Conly J. Aerosol generating procedures  
420 and risk of transmission of acute respiratory infections to healthcare workers: a systematic  
421 review. *PLOS ONE*. 2012.
- 422 19. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for  
423 systematic reviews and meta-analyses: the PRISMA statement. *J Clin Epidemiol*.  
424 2009;62(10):1006-12.
- 425 20. Kuster SP, Coleman BL, Raboud J, McNeil S, De Serres G, Gubbay J, et al. Risk Factors  
426 for Influenza among Health Care Workers during 2009 Pandemic, Toronto, Ontario, Canada.  
427 *Emerging Infectious Diseases*. 2013;19(4):606-15.
- 428 21. MacIntyre CR, Seale H, Yang P, Zhang Y, Shi W, Almatroudi A, et al. Quantifying the  
429 risk of respiratory infection in healthcare workers performing high-risk procedures.  
430 *Epidemiology & Infection*. 2014;142:1802-8.
- 431 22. World Health Organization. Infection prevention and control of epidemic- and pandemic-  
432 prone acute respiratory infections in health care [Internet]. Geneva, Switzerland: World Health  
433 Organization; 2014 [Available from: <https://apps.who.int/iris/handle/10665/112656>].
- 434 23. Lynch JB, Davitkov P, Anderson DJ, Bhimraj A, Cheng VC, Guzman-Cottrill J, et al.  
435 Infectious Diseases Society of America Guidelines on Infection Prevention in Patients with  
436 Suspected or Known COVID-19 Arlington, United States: IDSA; 2020 [Available from:  
437 <https://www.idsociety.org/practice-guideline/covid-19-guideline-infection-prevention/>].
- 438 24. Kirkpatrick J, Mitchell C, Taub C, Kort S, Hung J, Swaminathan M. ASE Statement on  
439 Protection of Patients and Echocardiography Service Providers During the 2019 Novel  
440 Coronavirus Outbreak 2020 [Available from: [https://www.asecho.org/wp-](https://www.asecho.org/wp-content/uploads/2020/03/COVIDStatementFINAL4-1-2020_v2_website.pdf)  
441 [content/uploads/2020/03/COVIDStatementFINAL4-1-2020\\_v2\\_website.pdf](https://www.asecho.org/wp-content/uploads/2020/03/COVIDStatementFINAL4-1-2020_v2_website.pdf)].
- 442 25. Canadian Society of Respiratory Therapists. Position Statement on Procedures Creating a  
443 Heightened Risk of Infection During an Outbreak of a Communicable Respiratory Disease  
444 Ottawa, Canada 2020 [Available from: [https://www.csrt.com/wp-content/uploads/CSRT-](https://www.csrt.com/wp-content/uploads/CSRT-Procedures-Duringan-Outbreak-April-2020.pdf)  
445 [Procedures-Duringan-Outbreak-April-2020.pdf](https://www.csrt.com/wp-content/uploads/CSRT-Procedures-Duringan-Outbreak-April-2020.pdf)].
- 446 26. Thomas P, Baldwin C, Bissett B, Boden I, Gosselink R, Granger CL, et al. Physiotherapy  
447 management for COVID-19 in the acute hospital setting: Recommendations to guide clinical  
448 practice. 2020.
- 449 27. Alberta Health Services. Aerosol-Generating Medical Procedure Guidance Tool: novel  
450 coronavirus (COVID-19) Edmonton, Canada: Alberta Health Services; 2020 [Available from:  
451 <https://www.albertahealthservices.ca/topics/Page17091.aspx>].
- 452 28. Ontario Agency for Health Protection and Promotion (Public Health Ontario). Focus on:  
453 Aerosol generation from coughs and sneezes Toronto, Canada: Queens Printer for Ontario; 2020



454 [Available from: [https://www.publichealthontario.ca/-/media/documents/ncov/ipac/report-covid-](https://www.publichealthontario.ca/-/media/documents/ncov/ipac/report-covid-19-aerosol-generation-coughs-sneezes.pdf?la=en)  
455 [19-aerosol-generation-coughs-sneezes.pdf?la=en](https://www.publichealthontario.ca/-/media/documents/ncov/ipac/report-covid-19-aerosol-generation-coughs-sneezes.pdf?la=en).

456 29. Otto S, Babujee A, Neustaedter C, Tschritter D, Saxinger L, McRae A, et al. Among  
457 countries who are past their initial peak of COVID-19 cases, what proportion of total cases were  
458 in healthcare workers (HCW), and what is the estimated proportion of the total number of HCWs  
459 who developed COVID-19 from presumed occupational exposure? COVID-19 Scientific  
460 Advisory Group Rapid Response Report. [Rapid review]. In press 2020.

461 30. Ran L, Chen X, Wang Y, Wu W, Zhang L, Tan X. Risk Factors of Healthcare Workers  
462 with Corona Virus Disease 2019: A Retrospective Cohort Study in a Designated Hospital of  
463 Wuhan in China. Clin Infect Dis. 2020.

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497	<b>SUPPORTING INFORMATION CAPTIONS</b>
498	
499	A1 Appendix.docx: Additional File 1. Complete Search Strategy
500	
501	A2 Appendix.doc: Additional File 2. PRISMA 2009 Checklist
502	
503	A3 Appendix.docx: Additional File 3. Table of Excluded Articles